KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume78
Issue number2
DOIs
StatePublished - 25 Aug 2021

Bibliographical note

Funding Information:
Dr. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; B2017/BMD-3740 AGES CM 2-CM), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda. Dr. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute. All other authors declare that they have no conflicts of interest.

Funding Information:
This work was supported in part by the grant PI16/00359 and PI18/1275 (Fondo de Investigaciones Sanitarias, FIS, and FEDER), by Madrid Regional Government (R&D activities in Biomedicine S2017/BMD-3740 (AGES-CM 2-CM)) and Structural Funds of the European Union, and by the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) of the Instituto de Salud Carlos III.

Keywords

  • COVID-19
  • Disease management
  • Inflammatory bowel diseases
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement'. Together they form a unique fingerprint.

Cite this